Stephens Consulting’s Myriad Genetics MYGN Stock Holding History

Stephens Consulting’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-40	Closed	-$355	–	1689
2025 Q1	$355	Buy	+40	New	+$480	﹤0.01%	1307

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Stephens Consulting's MYGN Position: Q2 2025 in Review

Stephens Consulting sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 40 shares — an estimated $355 sold.

Stephens Consulting first reported a position in MYGN in Q1 2025 and held it in 1 quarter. The position peaked at $355 in Q1 2025. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

Stephens Consulting reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 40 Myriad Genetics shares in Q2 2025, an estimated $355.
Stephens Consulting first reported a position in Myriad Genetics in Q1 2025 and held it in 1 quarter.
Stephens Consulting's Myriad Genetics position peaked at $355 in Q1 2025.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.